Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from ERCHIVES-Reference-Cited by-同舟云学术

Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from ERCHIVES

Published:2016-03-24 Issue:9 Volume:36 Page:1275-1283
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver Int

Author:

Butt Adeel A.¹²³⁴,Yan Peng¹,Shaikh Obaid S.¹⁵,Chung Raymond T.⁶⁷,Sherman Kenneth E.⁸,

Affiliation:

1. VA Pittsburgh Healthcare System; Pittsburgh PA USA

2. Hamad Healthcare Quality Institute and Hamad Medical Corporation; Doha Qatar

3. Weill Cornell Medical College; Doha Qatar

4. Weill Cornell Medical College; New York NY USA

5. University of Pittsburgh School of Medicine; Pittsburgh PA USA

6. Massachusetts General Hospital; Boston MA USA

7. Harvard Medical School; Boston MA USA

8. University of Cincinnati College of Medicine/UC Health; Cincinnati OH USA

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/liv.13103/fullpdf

Reference26 articles.

1. Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort;Backus;Aliment Pharmacol Ther,2014

2. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients;Butt;Clin Infect Dis,2012

3. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial;Lawitz;Lancet Infect Dis,2013

4. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial;Kowdley;Lancet,2013

5. Simeprevir with peginterferon/ribavirin for treatment-naive hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial;Hayashi;J Hepatol,2014

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Self-reported and measured adherence to hepatitis C direct-acting antiviral therapy and sustained virologic response among people who inject drugs: The HERO study;International Journal of Drug Policy;2024-01

2. Perspectives on Adherence From the ACTG 5360 MINMON Trial: A Minimum Monitoring Approach With 12 Weeks of Sofosbuvir/Velpatasvir in Chronic Hepatitis C Treatment;Clinical Infectious Diseases;2023-01-24

3. Efficacy and Safety of Sofosbuvir and Ribavirin in an Italian Cohort of HCV Genotype 2 Elderly Cirrhotic Patients;The Eurasian Journal of Medicine;2022-06-03

4. Development and Validation of a Questionnaire to Measure Medication Adherence to Direct-Acting Agents in Patients with Hepatitis C;Pharmaceutics;2021-10-14

5. The impact of public coverage of newer hepatitis C medications on utilization, adherence, and costs in British Columbia;PLOS ONE;2021-03-01